Fill out the Form Below to Watch the Video:

Microbial Expression Systems Get A Much Needed Upgrade

For years, the biologics industry has struggled with inefficient microbial expression systems for producing proteins and antibodies that they need to manufacture new biopharmaceuticals. Difficulties with low titers, poor product quality, impurities in samples, and capacity constraints are just some of the challenges that scientists have with legacy systems.

Scientists at KBI Biopharma, led by Erik Nordwald, PhD, worked tirelessly for over two years to develop a novel state-of-the-art microbial cell line development platform that addresses these challenges. The new PUREplatform™ solution provides all the functionality that scientists need for optimal therapeutic protein production and development. 

Let's Connect

If you are interested in learning more about KBI’s work in process development, you can reach out to our team.